> Alantos Pharmaceuticals of Cambridge, MA has signed a collaboration deal for its lead compound, ALS 2-0426 for Type 2 diabetes, with France's Servier. Alantos stands to gain $75 million in up front fees and milestones. Release
> Millipore has opened its $50 million R&D center in Bedford, MA. Release
> Chutes & Ladders: Threshold Pharmaceuticals CFO and COO Michael Ostrach is resigning his posts. Report
> Organon and BrainCells say they will collaborate on the development of new CNS drugs. Report
> ProNAi Therapeutics has arranged $6.65 million in bridge financing. Report
> Axial Biotech has raised a small round of venture capital. Report
> Wyeth has extended a deal that gives it access to Affymetrix's GeneChip microarray technology by three years. Report
And Finally… Inspired by a website, a rush of patients complaining of the same mysterious symptoms has spurred the CDC to see if two clusters are indeed the result of Morgellons disease. Article